Date: Feb. 25th, 2021 Your Name: Junichi Shimamura Manuscript Title: Systematic Review and Meta-analysis of Time-to-Event Long-Term Outcomes following the Ross Procedure Manuscript number (if known): JTD-23-326-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	X None	
'	meetings and/or travel		
	meetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
0		Y N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other	<u>├</u>	
	services		
13	Other financial or non-	XNone	
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: 05/29/2023 Your Name: Shinichi Fukuhara Manuscript Title: Systematic Review and Meta-analysis of Time-to-Event Long-Term Outcomes following the Ross Procedure

Manuscript number (if known): JTD-23-326-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	-	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone	
3	Royalties or licenses	_xNone	
4	Consulting fees	None	Terumo Aortic

			1
			Artivion
			Medtronic
5	Payment or honoraria for	None	Medtronic
	lectures, presentations,		Edwards Lifesciences
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_xNone	
	testimony		
7	Support for attending	_xNone	
	meetings and/or travel		
8	Patents planned, issued or	x None	
0	•	xNone	
	pending		
9	Douticipation on a Data	V Neza	
9	Participation on a Data	xNone	
	Safety Monitoring Board or Advisory Board		
10		N	
10	Leadership or fiduciary role	None	Artivion PERSEVERE Trial Steering Committee
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_xNone	
12	Receipt of equipment,	_xNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_xNone	
	financial interests		

Dr. Fukuhara serves as a consultant for Terumo Aortic, Artivion and Medtronic Inc. and has received speakers' honoraria from Edwards Lifesciences and Medtronic Inc.

Please place an "X" next to the following statement to indicate your agreement:

Date: Feb. 21st, 2023 Your Name: Yujiro Yokoyama Manuscript Title: Systematic Review and Meta-analysis of Time-to-Event Long-Term Outcomes following the Ross Procedure Manuscript number (if known): JTD-23-326-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

lectures, speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of material writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of material writing, g services			
Speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	nt or honoraria for	XNone	
manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Patents p safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services	es, presentations,		
educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	-		
 Payment testimon Support meetings Patents pending Participa Safety M Advisory Leadersh in other committe group, patents pending Stock or Receipt of materials writing, generation services 	cript writing or		
testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Number7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	nt for expert	XNone	
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generation of services 	ony		
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generation of services 			
 Patents pending Participa Safety M Advisory Leadersh in other committe group, participal safety M Advisory Stock or Receipt of materials writing, generation services 	rt for attending	XNone	
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g	ngs and/or travel		
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g services	s planned, issued or	XNone	
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	ıg		
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	pation on a Data	X None	
Advisory10Leadersh in other committi group, pr11Stock or12Receipt of materials services	Monitoring Board or		
 10 Leadersh in other committe group, particular sector of the sector of t			
 in other committing group, particular 11 Stock or 12 Receiption materials writing, services 	ship or fiduciary role	X None	
committe group, pi11Stock or12Receipt of materials writing, g services	er board, society,		
group, pa 11 Stock or 12 Receipt of materials writing, g services	ittee or advocacy		
11Stock or12Receipt of materials writing, g services	paid or unpaid		
12 Receipt of materials writing, g services		X None	
materials writing, g services			
materials writing, g services			
materials writing, g services			
writing, g services	t of equipment,	X_None	
services	als, drugs, medical		
	_		
13 Other fin			
	financial or non-	XNone	
financial	al interests		
		XNone	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: Feb. 25th, 2021 Your Name: Hisato Takagi Manuscript Title: Systematic Review and Meta-analysis of Time-to-Event Long-Term Outcomes following the Ross Procedure Manuscript number (if known): JTD-23-326-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

lectures, speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committe group, pi11Stock or12Receipt of materials writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committe group, pi11Stock or12Receipt of materials writing, g services			
Speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	nt or honoraria for	XNone	
manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Patents p safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services	es, presentations,		
educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	-		
 Payment testimon Support meetings Patents pending Participa Safety M Advisory Leadersh in other committe group, patents pending Stock or Receipt of materials writing, generation services 	cript writing or		
testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Number7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	nt for expert	XNone	
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generation of services 	ony		
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generation of services 			
 Patents pending Participa Safety M Advisory Leadersh in other committe group, participal safety M Advisory Stock or Receipt of materials writing, generation services 	rt for attending	XNone	
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g	ngs and/or travel		
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g services	s planned, issued or	XNone	
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	ıg		
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	pation on a Data	X None	
Advisory 10 Leadershin other committigroup, progroup, program, p	Monitoring Board or		
 10 Leadersh in other committing roup, particular sector sec			
 in other committing group, particular 11 Stock or 12 Receiption materials writing, services 	ship or fiduciary role	X None	
committe group, pi11Stock or12Receipt of materials writing, g services	er board, society,		
group, pa 11 Stock or 12 Receipt of materials writing, g services	ittee or advocacy		
11Stock or12Receipt of materials writing, g services	paid or unpaid		
12 Receipt of materials writing, g services		X None	
materials writing, g services			
materials writing, g services			
materials writing, g services			
writing, g services	t of equipment,	X_None	
services	als, drugs, medical		
	_		
13 Other fin			
	financial or non-	XNone	
financial	al interests		
		XNone	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: 05/29/2023 Your Name: Maral Ouzounian Manuscript Title: Systematic Review and Meta-analysis of Time-to-Event Long-Term Outcomes following the Ross Procedure Manuscript number (if known): JTD-23-326-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding,	Time frame: Since the initial X_None	
	provision of study materials, medical writing, article		
	processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	X None	
	in item #1 above).		
3	Royalties or licenses	X None	
4	Consulting fees	X_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None	
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

None

Please place an "X" next to the following statement to indicate your agreement:

Date: May. 21st, 2023 Your Name: Toshiki Kuno Manuscript Title: Systematic Review and Meta-analysis of Time-to-Event Long-Term Outcomes following the Ross Procedure Manuscript number (if known): JTD-23-326-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
6	educational events	X None	
0	Payment for expert testimony		
7	Support for attending meetings and/or travel	X_None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement: